Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 533-545

  Bains, Onkar S ^a   Grigliatti, Thomas A ^a   Reid, Ronald E ^a   Riggs, K Wayne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE; CARBONYL REDUCTASE; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; HISTIDINE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; KINETICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ALCOHOL OXIDOREDUCTASES; ALDEHYDE REDUCTASE; BIOCATALYSIS; DAUNORUBICIN; DOXORUBICIN; GENE FREQUENCY; GLYCERALDEHYDE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; INDANS; KINETICS; MITOCHONDRIAL PROTEINS; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); OXIDOREDUCTASES; PHENANTHRENES; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; VITAMIN K 3;

EID: 78649613721     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173179     Document Type: Article

References (40)

1. Bains OS, Karkling MJ, Grigliatti TA, Reid RE, and Riggs KW (2009) Two nonsynonymous single-nucleotide polymorphisms of carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos 37:1107-1114.
2. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, and Riggs KW (2010) Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332:755-763.
3. Bains OS, Takahashi RH, Pfeifer TA, Grigliatti TA, Reid RE, and Riggs KW (2008) Two allelic variants of aldo-ketoreductase 1A1 exhibit reduced in vitro metabolism of daunorubicin. Drug Metab Dispos 36:904-910.
4. Barry E, Alvarez JA, Scully RE, Miller TL, and Lipshultz SE (2007) Anthracyclineinduced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 8:1039-1058.
5. Barski OA, Tipparaju SM, and Bhatnagar A (2008) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553-624.
6. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, and Bhatia S (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-2795.
7. Burczynski ME, Harvey RG, and Penning TM (1998) Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37:6781-6790.
8. Byrns MC, Steckelbroeck S, and Penning TM (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone-dependent and hormone-independent malignancies. Biochem Pharmacol 75:484-493.
9. Cortés-Funes H and Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56-60.
10. Cummings J, Anderson L, Willmott N, and Smyth JF (1991) The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 27:532-535.
11. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431-444.
12. Deng S and Wojnowski L (2007) Genotyping the risk of anthracycline- induced cardiotoxicity. Cardiovasc Toxicol 7:129-134.
13. Di Costanzo L, Penning TM, and Christianson DW (2009) Aldo-keto reductases in which the conserved catalytic histidine is substituted. Chem Biol Interact 178:127-133.
14. Di Luccio E, Elling RA, and Wilson DK (2006) Identification of a novel NADH-specific aldo-keto reductase using sequence and structural homologies. Biochem J 400:105-114.
15. Endo S, Matsunaga T, Kitade Y, Ohno S, Tajima K, El-Kabbani O, and Hara A (2008) Human carbonyl reductase 4 is a mitochondrial NADPH-dependent quinone reductase. Biochem Biophys Res Commun 377:1326-1330.
16. Fassas A and Anagnostopoulos A (2005) The use of liposomal daunorubicin (Dauno-Xome) in acute myeloid leukemia. Leuk Lymphoma 46:795-802.
17. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, and Perry MC (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685-7696.
18. Gianni L, Salvatorelli E, and Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7:67-71.
19. Hoffmann F and Maser E (2007) Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87-144.
20. Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, Sadoun A, Guilhot F, Casassus P, and Ifrah N (2001) Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia 15:898-902.
21. Jez JM, Flynn TG, and Penning TM (1997) A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 54:639-647.
22. Jin Y and Penning TM (2007) Aldo-keto reductases and bioactivation/ detoxification. Annu Rev Pharmacol Toxicol 47:263-292.
23. Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, et al. (2008) Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36: 2113-2120.
24. Komoto J, Yamada T, Watanabe K, and Takusagawa F (2004) Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43:2188-2198.
25. Kume T, Iwasa H, Shiraishi H, Yokoi T, Nagashima K, Otsuka M, Terada T, Takagi T, Hara A, and Kamataki T (1999) Characterization of a novel variant (S145C/L311V) of 3α-hydroxysteroild/dihydrodiol dehydrogenase in human liver. Pharmacogenetics 9:763-771.
26. Lakhman SS, Ghosh D, and Blanco JG (2005) Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 33:254-257.
27. Lipp HP and Bokemeyer C (1999) Anthracyclines and other intercalating agents, in Anticancer Drug Toxicity: Prevention, Management and Clinical Pharmacokinetics (Lipp HP, ed) pp 81-113, Marcel Dekker, New York.
28. Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, and Maser E (2006) Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464-470.
29. Matsunaga T, Shintani S, and Hara A (2006) Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1-18.
30. Matsuura K, Hara A, Deyashiki Y, Iwasa H, Kume T, Ishikura S, Shiraishi H, and Katagiri Y (1998) Roles of the C-terminal domains of human dihydrodiol dehydrogenase isoforms in the binding of substrates and modulator: probing with chimaeric enzymes. Biochem J 336:429-436.
31. Menna P, Recalcati S, Cairo G, and Minotti G (2007) An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80-85. (Pubitemid 47339872)
32. Mordente A, Meucci E, Martorana GE, Giardina B, and Minotti G (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83-88.
33. O'Connor T, Ireland LS, Harrison DJ, and Hayes JD (1999) Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 343:487-504.
34. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, and Hara A (1995) Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221-227.
35. Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
36. Penning TM (2003) Introduction and overview of the aldo-keto reductase superfamily, in Aldo-Keto Reductases and Toxicant Metabolism (Penning TM, Petrash JM, eds) pp 3-22, American Chemical Society, Washington, DC.
37. Penning TM and Drury JE (2007) Human aldo-keto reductases: function, gene regulation, and single-nucleotide polymorphisms. Arch Biochem Biophys 464:241-250.
38. Plebuch M, Soldan M, Hungerer C, Koch L, and Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255:49-56.
39. Schlegel BP, Ratnam K, and Penning TM (1998) Retention of NADPH-linked quinine reductase activity in an aldo-keto reductase following mutation of the catalytic tyrosine. Biochemistry 37:11003-11011.
40. Takahashi RH, Bains OS, Pfeifer TA, Grigliatti TA, Reid RE, and Riggs KW (2008) Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos 36:991-994.